The advent of immunohistochemistry in carcinoma of unknown primary site: A major progress

Carcinoma of an Unknown Primary Site

Volumn , Issue , 2006, Pages 25-35

  Voigt, Jean Jacques ^a   Mathieu, Marie Christine ^b   Bibeau, Frédéric ^c  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46949090237     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (40)

1. Nissenblatt MJ. The CUP syndrome (carcinoma of unknown primary). Cancer Treat Rev 1981; 8:211-224.
2. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994; 12:1272-1280.
3. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 1997; 15:2056-2066.
4. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either Gemcitabine or Irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479-3482.
5. De Young BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000; 17: 184-193.
6. Chan JKC. Advances in immunohistochemistry: impact on surgical pathology practice. Semin Diagn Pathol 2000; 17:170-177.
7. Dabbs DJ, ed. Carcinomatous differentiation and metastatic carcinoma of unknown primary. Diagnostic Immunohistochemistry. New York: Churchill Livingstone, 2002:163-196.
8. Bugat R, Bataillard A, Lesimple T, et al. Standards, options et recommandations 2002 pour la prise en charge des patients atteints de carcinome de site primitif inconnu (rapport integral). FNCLCC. Montrouge: J Libbey Eurotext, 2004.
9. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 2003; 89(suppl 1):59-66.
10. Lesimple T, Voigt JJ, Bataillard A, et al. Recommandations pour la pratique clinique: Standards, Options et Recommandations 2002 pour le diagnostic des carcinomes de site primitif inconnu. Bull Cancer 2003; 90:1071-1096.
11. Gown AM, Bacchi CE. Cost effective immunohistochemistry. 85th Annual Meeting. United States and Canadian Academy of Pathology. Washington, March, 1996.
12. Suster S, Moran CA, Dominguez-Malagon H, Quevedo-Blanco P. Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases. Hum Pathol 1998; 29:737-742.
13. Busam K. The use and application of special techniques in assessing melano-cytic tumours. Pathology 2004; 36:462-469.
14. Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol 2003; 16:481-490.
15. Coindre JM. Immunohistochemistry in the diagnosis of soft tissue tumours. Histopathology 2003; 43:1-16.
16. Wick MR. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 2000; 17:194-203.
17. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 2002; 38:758-763.
18. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003; 42:137-140.
19. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma. An immunohistochemical comparison to carcinoem-bryonic antigen, CD10, and Alpha-Fetoprotein. Am J Surg Pathol 2002; 26: 978-988.
20. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol 2001; 25:1297-1303.
21. Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocar-cinoma. A histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 2002; 26:989-997.
22. Terracciano LM, Glatz K, Mhawech P, et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma. An immunohistochemical and molecular study of eight cases. Am J Surg Pathol 2003; 27:1302-1312.
23. Avery AK, Beckstead J, Renshaw A, Corless CL. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000; 24:203-210.
24. Barbareschi M, Murer B, Colby TV, et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 2003; 27:141-149.
25. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX-2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohisto-chemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003; 27:303-310.
26. Li MK, Folpe AL. CDX-2, a new marker for adenocarcinoma of gastrointestinal origin. Adv Anat Pathol 2004; 11:101-105.
27. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002; 26:767-773.
28. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract. A useful marker in the diagnosis of meso-nephric, trophoblastic and clear cell tumors. Am J Surg Pathol 2003; 27:178-186.
29. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombo-modulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003; 27:1-10.
30. Nieder C, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma. Curr Treat Options Oncol 2002; 3:33-40.
31. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology 2001; 39:9-16.
32. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types. An immuno-histochemical analysis of 596 tumors in comparison with epithelioid mesothe-liomas of the pleura. Am J Surg Pathol 2003; 27:150-158.
33. Baselga J. New therapeutic agents targeting the epidermal growth factor. J Clin Oncol 2000; 18:54-59.
34. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adeno-carcinoma of unknown primary site. J Clin Oncol 2000; 18:623-635.
35. Voigt JJ, Culine S, Le SimpleT, et al. Carcinomes de site primitif inconnu. HER-2, EGFR et c-kit sont-ils de nouvelles cibles therapeutiques? Ann Pathol 2003; 23(suppl 1):126.
36. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14:262-270.
37. Le Guen Y, Sabatier L, Le Chevalier T, Soria JC. Therapeutiques moleculaires ciblees en cancerologie bronchique. Bull Cancer 2003; 90:1055-1061.
38. Fizazi K, Voigt JJ, Lesimple T, et al. Carcinoma of unknown primary (CUP): are tyrosine kinase receptors HER-2, EGF-R, and c-kit suitable targets for therapy? Proc Am Soc Clin Oncol 2003; 22:883.
39. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
40. Coindre JM, Blanc-Vincent MP, Collin F, Mac Grogan G, Balaton A, Voigt JJ. Standards, options et recommandations: conduite a tenir devant une lesion de diagnostic anatomo-cytopathologique difficile en cancerologie. Ann Pathol 2003; 23:460-470.